Admin Core
管理核心
基本信息
- 批准号:10588206
- 负责人:
- 金额:$ 71.02万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-01-02 至 2024-12-31
- 项目状态:已结题
- 来源:
- 关键词:AccountingAcuteAcute Lung InjuryAdvisory CommitteesAffectAnimalsBiologyBiomedical ResearchCenters of Research ExcellenceClimateCollaborationsCommunitiesDataDedicationsDiseaseEducational workshopEnsureEnvironmentEquipmentEthicsEvaluationExtrinsic asthmaFeedbackFelis catusFosteringFoundationsFundingFunding AgencyGoalsGrantHumanIndividualIndustryInfluenzaInfrastructureInstitutionInternationalKnowledgeLeadershipLifeLouisianaLungLung diseasesMediatingMentorsModernizationMolecularMolecular BiologyMonitorNational Institute of General Medical SciencesOutcomePathogenesisPhasePilot ProjectsPopulationPostdoctoral FellowProgram Research Project GrantsPublicationsRecordsRegulationResearchResearch PersonnelResearch SupportRespiratory DiseaseScienceSenior ScientistServicesStrategic PlanningTechnologyTrainingTraining ActivityTuberculosisUnited States National Institutes of HealthUniversitiesUniversity adminstrationVeterinary MedicineVeterinary SchoolsWritingcareercareer developmentchronic respiratory diseasecomparativegraduate studentimmunopathologyimprovedinter-institutionalmeetingsmemberprogramsrecruitsuccesssymposiumundergraduate studentweb site
项目摘要
PROJECT SUMMARY
The objective of the Center for Lung Biology and Disease (aka Lung COBRE) at Louisiana State University
(LSU) is to elucidate the molecular and cellular pathogenesis of life-threatening acute and chronic respiratory
diseases affecting human population. The Administrative Core (AC) will provide administrative support,
organization, coordination, and efficient management necessary to ensure the success of the lung COBRE and
of our Promising Junior Investigators (PJIs). This Core will also provide accounting support that will ensure
appropriate fiscal and scientific oversight, monitoring, and compliance with federal and institutional grant
management regulations. The COBRE will be administered within Pathobiological Sciences (PBS) in
collaboration with Comparative Biomedical Sciences (CBS) in the LSU School of Veterinary Medicine (LSU
SVM). In the current funding climate, success for the lung COBRE depends on numerous factors: 1) an
outstanding personalized mentoring program; 2) renovated animal holding and research space with state-of-
the-art facilities; 3) access to modern equipment and cutting-edge technology through Scientific Cores; 4)
remove excessive administrative and service burdens for PJIs; and 5) foster collaborations within the institution
and between institutions in Louisiana through NIGMS-funded INBRE, COBRE and LA CaTS. To promote the
career development of PJIs, we have assembled senior scientists with outstanding track record to serve on
Internal (IAC) and external advisory (EAC) as well as mentoring committees (MC). The PJI’s individual projects
will be supported by Pulmonary Immunopathology (PIP) and Molecular Biology (MB) cores to leverage
excellent local strengths in biomedical research. To ensure success of the lung COBRE, we have developed a
15-year strategic plan to establish (Phase I - 5 years), expand (Phase II - 5 years), and sustain (Phase III - 5
years) lung COBRE to become an independent center and to attain national and international recognition
through multiple sources of funding, such as federal, state, foundations, industry, and university.
项目总结
路易斯安那州立大学肺生物学和疾病中心(又名肺眼镜蛇)的目标
(LSU)是为了阐明危及生命的急性和慢性呼吸道疾病的分子和细胞发病机制。
影响人类人口的疾病。行政核心(AC)将提供行政支持,
组织、协调和有效的管理是确保肺科医生和
我们有前途的初级调查员(PJI)。该核心还将提供会计支持,以确保
适当的财政和科学监督、监测和遵守联邦和机构拨款
管理规定。Cobre将在#年在病理生物科学(PBS)范围内实施
与路易斯安那州立大学兽医学院(LSU)比较生物医学(CBS)合作
支持向量机)。在目前的资金环境下,肺眼镜蛇的成功取决于许多因素:1)和
卓越的个性化指导计划;2)翻新的动物收容和研究空间,拥有最先进的
最先进的设施;3)通过科学核心获得现代设备和尖端技术;4)
消除PJI过多的行政和服务负担;以及5)促进机构内部的合作
以及路易斯安那州的机构之间通过NIGMS资助的INBRE、Cobre和LA CATS。为了促进
PJI的职业发展,我们聚集了具有出色记录的资深科学家服务于
内部(IAC)和外部咨询(EAC)以及指导委员会(MC)。PJI的个人项目
将得到肺免疫病理学(PIP)和分子生物学(MB)核心的支持,以利用
在生物医学研究方面具有出色的本土优势。为了确保肺科布雷的成功,我们开发了一种
建立(第一阶段-5年)、扩大(第二阶段-5年)和维持(第三阶段-5年)的15年战略计划
几年)Long Cobre成为一个独立的中心,并获得国内和国际的认可
通过多个资金来源,如联邦、州、基金会、行业和大学。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Samithamby Jeyaseelan其他文献
Samithamby Jeyaseelan的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Samithamby Jeyaseelan', 18)}}的其他基金
Host Immunity in Sepsis-Induced Systemic Infection
脓毒症引起的全身感染中的宿主免疫
- 批准号:
10615084 - 财政年份:2021
- 资助金额:
$ 71.02万 - 项目类别:
Host Immunity in Sepsis-Induced Systemic Infection
脓毒症引起的全身感染中的宿主免疫
- 批准号:
10400027 - 财政年份:2021
- 资助金额:
$ 71.02万 - 项目类别:
Innate Immunity in Lung Infection-induced Sepsis
肺部感染引起的脓毒症的先天免疫
- 批准号:
10626167 - 财政年份:2018
- 资助金额:
$ 71.02万 - 项目类别:
Neutrophil Accumulation in Bacterial Pneumonia
细菌性肺炎中的中性粒细胞积聚
- 批准号:
7837294 - 财政年份:2009
- 资助金额:
$ 71.02万 - 项目类别:
相似海外基金
Combinatorial cytokine-coated macrophages for targeted immunomodulation in acute lung injury
组合细胞因子包被的巨噬细胞用于急性肺损伤的靶向免疫调节
- 批准号:
10648387 - 财政年份:2023
- 资助金额:
$ 71.02万 - 项目类别:
Inducible HMGB1 antagonist for viral-induced acute lung injury.
诱导型 HMGB1 拮抗剂,用于治疗病毒引起的急性肺损伤。
- 批准号:
10591804 - 财政年份:2023
- 资助金额:
$ 71.02万 - 项目类别:
MAP2K1 AND MAP2K2 IN ACUTE LUNG INJURY AND RESOLUTION
MAP2K1 和 MAP2K2 在急性肺损伤中的作用及缓解
- 批准号:
10741574 - 财政年份:2023
- 资助金额:
$ 71.02万 - 项目类别:
Lung epithelial cell-derived C3 in acute lung injury
肺上皮细胞衍生的 C3 在急性肺损伤中的作用
- 批准号:
10720687 - 财政年份:2023
- 资助金额:
$ 71.02万 - 项目类别:
Examining the role of TRMT1 and tRNA methylation in acute lung injury and ARDS
检查 TRMT1 和 tRNA 甲基化在急性肺损伤和 ARDS 中的作用
- 批准号:
10719249 - 财政年份:2023
- 资助金额:
$ 71.02万 - 项目类别:
Development of a new treatment for COVID-19-related acute lung injury targeting the microbiota-derived peptide corisin
针对微生物群衍生肽 corisin 开发治疗 COVID-19 相关急性肺损伤的新疗法
- 批准号:
23K07651 - 财政年份:2023
- 资助金额:
$ 71.02万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Probing immunovascular mechanobiology in pneumonia-associated acute lung injury at the single capillary level
在单毛细血管水平探讨肺炎相关急性肺损伤的免疫血管力学生物学
- 批准号:
10679944 - 财政年份:2023
- 资助金额:
$ 71.02万 - 项目类别:
The amyloid precursor protein protects against acute lung injury
淀粉样前体蛋白可预防急性肺损伤
- 批准号:
10575258 - 财政年份:2023
- 资助金额:
$ 71.02万 - 项目类别:
Role of macrophages and miRNA in regulating lung macrophage polarization and lung pathogenesis during respiratory virus-induced acute lung injury in normal and diabetic Syrian hamsters.
正常和糖尿病叙利亚仓鼠呼吸道病毒引起的急性肺损伤期间巨噬细胞和 miRNA 在调节肺巨噬细胞极化和肺部发病机制中的作用。
- 批准号:
10701207 - 财政年份:2023
- 资助金额:
$ 71.02万 - 项目类别:
Roles of N-glycans on neutrophil beta2 integrins in progression of acute lung injury
N-聚糖对中性粒细胞β2整合素在急性肺损伤进展中的作用
- 批准号:
10837431 - 财政年份:2023
- 资助金额:
$ 71.02万 - 项目类别: